Phase 2 dose-finding RCT (Cohort A, 100 analysed) in cutaneous or systemic lupus with active skin disease: enpatoran 25, 50 or 100 mg cut CLASI-A at week 16 by 64, 68 and 72 points vs 44 with placebo (dose-response p=0.0002).
RCTn = 102
Morand et al. Efficacy and safety of enpatoran, a Toll-like receptor 7/8 inhibitor, in patients with skin manifestations of cutaneous lupus erythematosus or systemic lupus erythematosus: findings from Cohort A of a multicentre, international, double-blind, placebo-controlled, dose-finding phase 2 trial